Webb6 apr. 2024 · Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) stock closed at 1.45 per share at the end of the most recent trading day (a 0.26 % change compared to the prior day closing price) with a volume of 31.69K shares and market capitalization of 3.58M.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in … Webb' v ' o } o Ç v u ] ] À ] v & µ v ¨ í ì X ð ì ' P y d Z µ ] / v X } u u } v ^ } l ¨ í X ñ î
Forum su Salarius Pharmaceuticals (SLRX) - Investing.com
WebbStock analysis for Salarius Pharmaceuticals Inc (SLRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. WebbView the latest Salarius Pharmaceuticals Inc. (SLRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. the priory hotel bury st edmunds
Salarius Announces Exercise Of Warrants For $3.5 Million Of …
Webb10 juni 2024 · Salarius Pharmaceuticals ( NASDAQ: SLRX) on Friday filed for resale of up to ~7M shares by selling stockholders, issuable on exercise of certain outstanding … Webb13 apr. 2024 · About SLRX. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. WebbSalarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. CEO David J. Arthur Employees 12 Headquarters Houston, Texas Founded 2014 sigma wireless ireland